目的 探討神香蘇合丸聯(lián)合替格瑞洛治療不穩(wěn)定心絞痛的臨床療效。方法 將康復(fù)大學(xué)青島中心醫(yī)院于2021年6月—2023年6月收治的不穩(wěn)定心絞痛患者98例，隨機(jī)分為對照組（49例）和治療組（49例）。對照組口服替格瑞洛片，首次治療負(fù)荷劑量為180 mg，隨后劑量為90 mg/次，2次/d。治療組在對照組的基礎(chǔ)上口服神香蘇合丸，0.7 g/次，1次/d。兩組患者治療6個月。觀察兩組患者臨床療效，比較治療前后兩組血清炎癥指標(biāo)超敏C反應(yīng)蛋白（hs-CRP）、白細(xì)胞介素-17（IL-17）和腫瘤壞死因子-α（TNF-α）水平，及血液高凝狀態(tài)指標(biāo)D-二聚體、全血低切黏度和全血高切黏度。結(jié)果 治療后，治療組的總有效率為93.88%，顯著高于對照組的79.59%（P＜0.05）。與治療前相比，治療后，兩組hs-CRP、IL-17、TNF-α、D-二聚體、全血低切黏度、全血高切黏度水平均明顯下降（P＜0.05），且與對照組比較，治療后治療組血清炎癥和血液高凝狀態(tài)指標(biāo)水平降低幅度更大（P＜0.05）。結(jié)論 神香蘇合丸聯(lián)合替格瑞洛治療不穩(wěn)定心絞痛療效確切，能有效改善患者炎癥反應(yīng)、血液高凝狀態(tài)，且安全性較好。

Objective To explore the therapeutic effect of Shenxiang Suhe Pills combined with ticagrelor in treatment of unstable angina. Methods Patients (98 cases) with unstable angina in Qingdao Central Hospital, University of Health and Rehabilitation Sciences from June 2021 to June 2023 were randomly divided into control (49 cases) and treatment (49 cases) group. Patients in the control group were po administered with Ticagrelor Tablets, the first treatment loading dose was 180 mg, and subsequent doses was 90 mg/time, twice daily. Patients in the treatment group were po administered with Shenxiang Suhe Pills on the basis of the control group, 0.7 g/time, once daily. Patients in two groups were treated for 6 months. After treatment, the clinical evaluations were evaluated, and the levels of serum inflammatory markers hs-CRP, IL-17 and TNF-α, and the levels of D-dimer, whole blood low shear viscosity and whole blood high shear viscosity in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 93.88%, which was significantly higher than 79.59% in the control group (P < 0.05). Compared with before treatment, the levels of hs-CRP, IL-17, TNF-α, D-dimer, whole blood low-shear viscosity, and whole blood high-shear viscosity decreased significantly in two groups after treatment (P < 0.05). Compared with the control group, the levels of serum inflammation and blood hypercoagulability indicators in the treatment group were decreased more significantly (P < 0.05). Conclusion The combination of Shenxiang Suhe Pills and ticagrelor has a definite therapeutic effect on unstable angina pectoris, which can effectively improve the patient's inflammatory response and blood hypercoagulability with good safety.

R972

山東省重點研發(fā)計劃項目（2021SFGC0508）